(Updates with the latest stock price movement in the headline and the first paragraph.)

ImmunityBio (IBRX) shares rose more than 8% in Friday trading after the company said it has completed manufacturing engineering programs NK2022 and NK2023, establishing a safe and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer, or M-ceNK, cell therapy platform.

The programs enrolled 64 healthy participants and cancer patients, who completed apheresis collection, the company said, adding that a single apheresis yields up to 5 billion M-ceNK cells good for 8 to 10 therapeutic doses. The collected cells were stored and used for process development and validation, ImmunityBio added.

10 cancer patients received their collected cells following the NK cell enrichment process, with 23 total doses administered. ImmunityBio said the trial demonstrated a successful repeat dosing and cryo-banking of M-ceNK cells, with no serious adverse events.

ImmunityBio also said a phase 1 trial of a combination of M-ceNK with Anktiva, or nogapendekin alfa inbakicept-pmln, in patients with relapsed or refractory tumors has been completed, demonstrating safety following infusion of the M-ceNK drug product.

Price: 8.47, Change: +0.65, Percent Change: +8.25